Hubei Biocause Heilen Pharmaceutical Co., Ltd.
SHZ: 301211.SZ0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- Shenzhen Stock Exchange
- Sector
- Basic Materials
- Industry
- Chemicals
- CEO
- Qun Liang
- Employees
- 1,012
- Headquarters
- Jingmen, China
- IPO year
- 2021
- Market cap
- CN¥3.3B
- Website
- https://biocause.com
Loading 301211…
Loading profile data…Frequently asked questions about 301211
What does Hubei Biocause Heilen Pharmaceutical Co., Ltd. (301211.SZ) do?
Hubei Biocause Heilen Pharmaceutical Co., Ltd. engages in the pharmaceutical, chemical, and new energy fuel businesses in China. It provides APIs and intermediates, and formulations; and dimethyl ether gas and chloropropionyl chloride chemical products. The company is based in Jingmen, China.
Where does 301211.SZ trade?
Hubei Biocause Heilen Pharmaceutical Co., Ltd. (301211.SZ) trades on the Shenzhen Stock Exchange.
What sector is 301211.SZ in?
Hubei Biocause Heilen Pharmaceutical Co., Ltd. (301211.SZ) operates in the Basic Materials sector, specifically in the Chemicals industry.
Who is the CEO of Hubei Biocause Heilen Pharmaceutical Co., Ltd.?
Qun Liang is the chief executive officer of Hubei Biocause Heilen Pharmaceutical Co., Ltd. (301211.SZ).
Where is Hubei Biocause Heilen Pharmaceutical Co., Ltd. headquartered?
Hubei Biocause Heilen Pharmaceutical Co., Ltd. is headquartered in China.
Does 301211.SZ pay a dividend?
Yes — Hubei Biocause Heilen Pharmaceutical Co., Ltd. (301211.SZ) paid a trailing twelve-month dividend of CNY 0.17 per share. Frequency and ex-dividend dates are tracked on the dividends tab.
When did 301211.SZ go public?
Hubei Biocause Heilen Pharmaceutical Co., Ltd. (301211.SZ) completed its initial public offering in 2021.